Background: Postmenopausal osteoporosis is a multifactorial disease. Genetic factors play an essential role in contributing to bone mineral density (BMD) variability, which ranges from 60 to 85%. Alendronate is used as the first line of pharmacological treatment for osteoporosis; however, some patients do not respond adequately to therapy with alendronate.
Aim: The aim of this work was to investigate the influence of combinations of potential risk alleles (genetic profiles) associated with response to anti-osteoporotic treatment in postmenopausal women with primary osteoporosis.
Methods: A total of 82 postmenopausal women with primary osteoporosis receiving alendronate (70 mg administered orally per week) for one year were observed. The bone mineral density (BMD; g/cm) of the femoral neck and lumbar spine was measured. According to BMD change, patients were divided into two groups: responders and non-responders to alendronate therapy. Polymorphic variants in , , , , , and genes were determined and profiles were generated from the combination of risk alleles.
Results: A total of 56 subjects were responders to alendronate and 26 subjects were non-responders. Carriers of the G-C-G-C profile (constructed from rs700518, rs1800795, rs2073618 and rs3102735) were predisposed to response to alendronate treatment ( = 0.001).
Conclusions: Our findings highlight the importance of the identified profiles for the pharmacogenetics of alendronate therapy in osteoporosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9956997 | PMC |
| http://dx.doi.org/10.3390/genes14020524 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alendronate partially rescues the periodontal defects in OIM mouse model of osteogenesis imperfecta.
Sci Rep
January 2025
Department of Growth and Development, University of Nebraska Medical Center, 4000 East Campus Loop South, 68583-0740, Lincoln, NE, US.
Osteogenesis imperfecta (OI) is a fairly common generalized connective disorder characterized by low bone mass, bone deformities and impaired bone quality that predisposes affected individuals to musculoskeletal fragility. Periodontal ligament (PDL)-alveolar bone and PDL-cementum entheses' roles under OI conditions during physiological loading and orthodontic forces remain largely unknown. In addition, bisphosphonates (e.
View Article and Find Full Text PDFSynthesis and characterization of a novel photothermal hydrogel composite with combined osteogenic and antibacterial activities.
Biomed Mater
January 2025
Department of Neurosurgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo 315040, Zhejiang, People's Republic of China.
Cranial defect repair remains a significant challenge in neurosurgery, and designing material complexes that can support bone regeneration while minimizing complications such as infection and inflammation could help alleviate this clinical challenge. This study presents a photothermal hydrogel complex with a controlled rapid gelation process, PDA-G-A-H, which integrates photothermal polydopamine nanoparticles (PDA NPs) with gentamycin (G) and alendronate acid (A). Furthermore, the incorporation of the injectable hydrogel Pluronic F127 and collagen (H) made this composite hydrogel (PDA-G-A-H) suitable for the multifaceted needs of cranial defects.
View Article and Find Full Text PDFCase Report: single low-dose of denosumab as a trigger of MRONJ development in a patient with osteoporosis after bisphosphonate therapy.
Front Oral Health
December 2024
Clinic of Maxillofacial Surgery, University Hospital Brno, Brno, Czechia.
Both denosumab (DMB) and bisphosphonates (BPs), antiresorptive drugs (ARDs) used for the treatment of osteoporosis and oncological disorders, are known for their potential to cause medication-related osteonecrosis of the jaws (MRONJ). Besides ARDs, statins were recently associated with MRONJ development, especially in patients taking higher doses of statins for a longer period of time. Here, we report a case of a female patient with osteoporosis using statins and treated with alendronate for 3 years who rapidly developed MRONJ stage III after only a single low dose of DMB.
View Article and Find Full Text PDFCombining systemic and local osteoporosis treatments: A longitudinal in vivo microCT study in ovariectomized rats.
Bone
December 2024
Laboratory of Biomechanical Orthopedics, Institute of Bioengineering, EPFL, Lausanne, Switzerland.
Introduction: Managing osteoporotic patients at immediate fracture risk is challenging, in part due to the slow and localized effects of anti-osteoporotic drugs. Combining systemic anti-osteoporotic therapies with local bone augmentation techniques offers a promising strategy, but little is known about potential interactions. We hypothesized that integrating systemic treatments with local bone-strengthening biomaterials would have an additive effect on bone density and structure.
View Article and Find Full Text PDFInhibition of osteocyte apoptosis does not prevent iron overload-induced bone resorption and bone loss.
Biochem Biophys Res Commun
January 2025
Department of Spine Surgery, People's Hospital of Longhua, Shenzhen, 518109, Guangdong, China; Department of Osteoporosis, Honghui Hospital, Xi'an Jiaotong University, Xi'an, 710054, Shaanxi, China. Electronic address:
Iron overload leads to apoptosis and increased expression of receptor activator of nuclear factor kappa-Β ligand (RANKL) in osteocytes, which in turn accelerates osteoclastogenesis. Since osteocytes are the main RANKL producers, we hypothesized that apoptotic osteocytes increase RANKL expression in osteocytes, which in turn stimulates osteoclastogenesis and bone resorption. In this study, alendronate or IG9402, a bisphosphonate (BP) analog which does not inhibit bone resorption, inhibited iron overload-induced osteocyte apoptosis and increased RANKL expression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!